BioSpecifics Technologies Corp. (NASDAQ:BSTC) is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. BioSpecifics Technologies Corp. (NASDAQ:BSTC) stock performance was 2.14% in last session and finished the day at $27.16. Traded volume was 61,391.00 shares in the last session and the average volume of the stock remained 27,510.00 shares. The beta of the stock remained 0.90. BioSpecifics Technologies Corp. (NASDAQ:BSTC) insider ownership is 1.40%.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its fourth quarter and full year 2013 financial results on Tuesday, March 25, 2014, after the U.S. financial markets close. Five Prime Therapeutics Inc. (NASDAQ:FPRX) dropped -1.00% to $22.76 yesterday on volume of 319,016.00 shares. The intra-day range of the stock was $21.50 – $23.33. Five Prime Therapeutics Inc. (NASDAQ:FPRX) has a market capitalization of 60.02 million.

During the last week, New Jersey based IGI Laboratories, Inc. (NYSEMKT:IG) announced that the U.S. Food and Drug Administration (FDA) has given its first approval for its abbreviated new drug application (ANDA). IGI Laboratories, Inc. (NYSEMKT:IG)’s stock on March 18, 2014 reported a higher of 9.96% to the closing price of $5.85. Its fifty two weeks range is $1.24 – $5.87. The total market capitalization recorded 253.87 million. The overall volume in the last trading session was 620,265.00 shares. In its share capital, IGI Laboratories, Inc. (NYSEMKT:IG) has 43.40 million outstanding shares.

Durata Therapeutics (NASDAQ:DRTX) shares reached a new 52-week high during trading on Tuesday after Jefferies Group raised their price target on the stock from $10.00 to $12.40, Analyst Ratings Network reports. The stock traded as high as $15.03 and last traded at $14.74, with a volume of 548,213 shares. The stock had previously closed at $13.91. On Tuesday, shares of Durata Therapeutics Inc. (NASDAQ:DRTX) advanced 5.39% to close the day at $14.66. Company monthly performance is recorded as 14.80%. Durata Therapeutics Inc. (NASDAQ:DRTX) quarterly revenue growth is 20.36%.